EPHA2 and urinary bladder cancer: Further, evaluation of EPHA2 inhibitors in a non-malignant cell line HEK293 demonstrated that both preventive and therapeutic pharmacological inhibition of EPHA2 kinase activity by dasatinib and ALW-II-41-27 reduces uropathogen infection comparable to the treatment outcome observed in 5637 bladder cancer epithelial cells (Figure S2A,B).